SillaJen
215600.KQ
2.30 USD
-0.06
-2.54%
s
Overview
Last close
2.30 usd
Market cap
317.94M usd
52 week high
3.48 usd
52 week low
1.28 usd
Target price
N/A usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
59.5456
Price/Book Value
4.0805
Enterprise Value
268.56M usd
EV/Revenue
50.6684
EV/EBITDA
-23.7838
Key financials
Revenue TTM
5.30M usd
Gross Profit TTM
1.75M usd
EBITDA TTM
-16.20M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
88.80M usd
Net debt
N/A usd
About
SillaJen, Inc. engages in developing technologies and products using genetic engineering in South Korea. The company develops Pexa-Vec, which is in phase 2 clinical trial to treat renal Cell Carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. It also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-600 Series and JX-970 to treat solid tumors and is in preclinical trial. SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea.
- Symbol215600.KQ
- ExchangeKQ
- IsinKR7215600008
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CEODr. Eun-Sang Moon D.D.S., DDS, M.D.
- HeadquarterSeoul
- Web sitehttps://www.sillajen.com
